GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » PE Ratio

Jasper Therapeutics (Jasper Therapeutics) PE Ratio : At Loss (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-09), Jasper Therapeutics's share price is $24.52. Jasper Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.13. Therefore, Jasper Therapeutics's PE Ratio for today is At Loss.

Jasper Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-1.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.13.

As of today (2024-06-09), Jasper Therapeutics's share price is $24.52. Jasper Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.20. Therefore, Jasper Therapeutics's PE Ratio without NRI ratio for today is At Loss.

Jasper Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-1.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.20.

During the past 3 years, the average EPS without NRI Growth Rate was -123.30% per year.

During the past 4 years, Jasper Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -123.30% per year. The lowest was -123.30% per year. And the median was -123.30% per year.

Jasper Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-1.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.13.

Back to Basics: PE Ratio


Jasper Therapeutics PE Ratio Historical Data

The historical data trend for Jasper Therapeutics's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics PE Ratio Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PE Ratio
N/A At Loss At Loss At Loss

Jasper Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Jasper Therapeutics's PE Ratio

For the Biotechnology subindustry, Jasper Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's PE Ratio falls into.



Jasper Therapeutics PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Jasper Therapeutics's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=24.52/-19.130
=-1.28(At Loss)

Jasper Therapeutics's Share Price of today is $24.52.
Jasper Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.13.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Jasper Therapeutics  (NAS:JSPR) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Jasper Therapeutics PE Ratio Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jasper Therapeutics (Jasper Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
Thomas G Wiggans director
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal officer: Chief Operating Officer C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell director, officer: President, CEO & Director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French director C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster director, 10 percent owner 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel 10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p. 10 percent owner 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade 10 percent owner C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Jasper Therapeutics (Jasper Therapeutics) Headlines

From GuruFocus

Jasper Therapeutics Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 01-24-2023